Abstract
Bisindole derivatives 1–17 have been synthesized and evaluated for their in vitro β-glucuronidase inhibitory potential. Some of these derivatives showed β-glucuronidase inhibitory activity more potent than the standard d-sachharic acid. In addition, molecular docking studies were also carried out using the GOLD 3.0 program to predict their structure–activity relationship.
Bisindole analogs 1–17 were synthesized and evaluated for their in vitro β-glucuronidase inhibitory potential. Out of seventeen compounds, the analog 1 (IC50=1.62±0.04μM), 6 (IC50=1.86±0.05μM), 10 (IC50=2.80±0.29μM), 9 (IC50=3.10±0.28μM), 14 (IC50=4.30±0.08μM), 2 (IC50=18.40±0.09μM), 19 (IC50=19.90±1.05μM), 4 (IC50=20.90±0.62μM), 7 (IC50=21.50±0.77μM), and 3 (IC50=22.30±0.02μM) showed superior β-glucuronidase inhibitory activity than the standard (d-saccharic acid 1,4-lactone, IC50=48.40±1.25μM). In addition, molecular docking studies were performed to investigate the binding interactions of bisindole derivatives with the enzyme. This study has identified a new class of potent β-glucouronidase inhibitors.